come on in
bridging science, policy and advocacy
how we’re different the cancer collaborative is a hub for the cancer community. created to foster an environment of collaboration amongst science, policy and advocacy in order to make a meaningful contribution to cancer care. our goal is to co-create and collaborate with stakeholders to proactively identify the challenges and opportunities, prioritize them and work together to make action-oriented changes on how cancer care is delivered in canada and beyond. better outcomes for cancer patients in canada can only be achieved when we let go of old ideologies- embracing innovation, encouraging collaboration, creating collective purpose and fundamentally changing. bold ideas and fuelling dialogues that adapt and adopt to shifting paradigms.
we can be the catalyst for change
EXPLORE THE CANCER COLLABORATIVE
car-t cell therapy
accelerating adoption through collaboration
car-t cell therapy has entered clinical practice. such a paradigm-shifting and novel cancer therapy that relies on viral production, genetic- modification, cell expansion, quality control/quality analysis, as well as clinical application and toxicity management poses significant challenges to regulatory and reimbursement approval. .
continuing the conversation to overcome roadblocks to expand access
biosimilar medicines represent a rapidly emerging field that can offer improved accessibility to medicines for patients at reduced expenditure for healthcare systems that are tackling issues of sustainability. the next two years will be important for biosimilars uptake and impact. biosimilars uptake in oncology can positively impact the financial burden of healthcare systems with the cost savings being reallocated to improve overall health system outcomes, globally.
cracking the cancer code
personalized medicine and biomarkers present an incredible opportunity to revolutionize health care. it has the potential to change the way we think about, identify and manage cancer care. the impact on both clinical research and patient care will grow as our understanding and technologies improve transforming the delivery of cancer care to benefit both patients and cancer care systems.
immuno-oncology [IO] therapies continue to create breakthroughs however real world challenges and significant shifts in value across healthcare systems create barriers to access for patients.
EXPLORE THE EVENTS
with a growing burden of disease, an ageing population, increased cost and capacity challenges, and increasing drug prices- there is an urgent need to remove inefficiencies to improve the delivery of care and patient outcomes. real world evidence could significantly...